Search

Displaying results 3381 - 3390 of 10000 in total
  1. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. … [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.

  2. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  3. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. … Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms.

  4. Drug

    LTX-109

    go.drugbank.com/drugs/DB12711
    Investigational

    LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive, Skin Infections.

  5. Drug

    Lithium cation

    go.drugbank.com/drugs/DB01356
    ApprovedInvestigationalWithdrawn

    Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. … It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches.

  6. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264108] The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory … [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    TBX-1400

    go.drugbank.com/drugs/DB18263
    Investigational

    TBX-1400 consists of human donor hematopoietic stem and progenitor cells.

  8. Drug

    CA-170

    go.drugbank.com/drugs/DB15772
    Investigational

    CA-170 is a selective, small molecule inhibitor of PD-L1.

  9. Drug

    Neisseria meningitidis serogroup b nada protein antigen

    go.drugbank.com/drugs/DB10785
    ApprovedInvestigational

    Mixtures: BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 10 ADET İĞNESİZ, BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET 2 İĞNELİ
  10. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    In February 2022, tepotinib was approved for use in Europe.[L42200] … Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates